» Articles » PMID: 28878093

Implications of MicroRNA Dysregulation in the Development of Prostate Cancer

Overview
Journal Reproduction
Date 2017 Sep 8
PMID 28878093
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are non-coding small RNAs that target mRNA to reduce protein expression. They play fundamental roles in several diseases, including prostate cancer (PCa). A single miRNA can target hundreds of mRNAs and coordinately regulate them, which implicates them in nearly every biological pathway. Hence, miRNAs modulate proliferation, cell cycle, apoptosis, adhesion, migration, invasion and metastasis, most of them constituting crucial hallmarks of cancer. Due to these properties, miRNAs emerged as promising tools for diagnostic, prognosis and management of cancer patients. Moreover, they come out as potential targets for cancer treatment, and several efforts are being made to progress in the field of miRNA-based cancer therapy. In this review, we will summarize the recent information about miRNAs in PCa. We will recapitulate all the miRNAs involved in the androgen pathway and the biology of PCa, focusing in PCa initiation and progression. In particular, we will describe the miRNAs associated with cell proliferation, cell cycle and apoptosis in PCa, as well as invasion, adhesion and metastatic miRNAs. We will revise the recent progress made understanding the role of circulating miRNAs identified in PCa that might be useful for PCa patient stratification. Another key aspect to be discussed in this review is miRNAs' role in PCa therapy, including the miRNAs delivery.

Citing Articles

MicroRNA in prostate cancer: from biogenesis to applicative potential.

Luo X, Wen W BMC Urol. 2024; 24(1):244.

PMID: 39506720 PMC: 11539483. DOI: 10.1186/s12894-024-01634-1.


miR-889-3p targeting BMPR2 promotes the development of retinoblastoma via JNK/MAPK/ERK signaling.

Gao Y, Du P Sci Rep. 2024; 14(1):7277.

PMID: 38538669 PMC: 10973389. DOI: 10.1038/s41598-023-49994-2.


Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics.

Qin P, Chen H, Wang Y, Huang L, Huang K, Xiao G Cell Rep Med. 2023; 4(10):101231.

PMID: 37852187 PMC: 10591051. DOI: 10.1016/j.xcrm.2023.101231.


Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.

Rafikova G, Gilyazova I, Enikeeva K, Pavlov V, Kzhyshkowska J Int J Mol Sci. 2023; 24(16).

PMID: 37628978 PMC: 10454494. DOI: 10.3390/ijms241612797.


Novel gene signature for predicting biochemical recurrence-free survival of prostate cancer and PRAME modulates prostate cancer progression.

Kadeerhan G, Xue B, Wu X, Hu X, Tian J, Wang D Am J Cancer Res. 2023; 13(7):2861-2877.

PMID: 37559989 PMC: 10408486.